hVIVO is a full-service early phase CRO.
Specialists in First-in-Human (FiH) clinical trials, CRS delivers fast, EMA-compliant early-phase drug development services with expert subject recruitment, PK/PD analysis, and dose escalation support.
World leading CRO in infectious and respiratory human challenge trials, offering over 14 validated models, state of the art labs & rapid recruitment.
Phase II–III infectious, respiratory, and cardiometabolic clinical trials across UK and Germany, with expert-led design, rapid recruitment, and advanced diagnostic capabilities.
CRS Clinical Research Services, part of the hVIVO Group, delivers end-to-end clinical pharmacology trial solutions with a focus on early-phase development and therapeutic specialisation.
Data Management and Biostatistics
Comprehensive data management and biostatistics support for clinical trials, ensuring accurate data capture, analysis, and timely, high-quality study results.
Our experienced, GCP-certified medical monitors provide trusted leadership for externally sponsored trials.
Accurate, compliant medical writing for clinical, regulatory, and safety documents - tailored to your needs.
Expert coordination ensuring timely, high-quality project delivery.
Rigorous standards and oversight to ensure compliance and data integrity across all processes.
Reliable clinical trial recruitment with over 400,000 volunteers, advanced CRM technology, and tailored participant matching to accelerate your study success.
Expert regulatory affairs support for seamless drug development, from submission preparation to ongoing trial compliance and final reporting.
World-class in-patient clinical trial sites across the UK and Germany, offering over 150 beds for early-phase, infectious disease, and specialist studies including advanced quarantine, PK/PD, and biosafety capabilities.
Five integrated outpatient clinical trial sites across the UK and Germany, offering over 1,000 weekly participant screenings, on-site IMP administration, and advanced laboratory capabilities.
Expert support in study setup and data analysis.
Optimising clinical development through expert PK/PD analysis and strategic insight across all phases.
Expert CMC support to ensure safe, consistent, and regulatory-ready drug development from concept to market.
Advancing drug candidates with tailored, expertly managed non-clinical development strategies.
Expert regulatory affairs support for seamless drug development, from submission preparation to ongoing trial compliance and final reporting.
hLAB specialises in respiratory infection samples obtained from hVIVO. Governed by the Human Tissue Authority, our Biobank houses a diverse range of human biofluids. In addition our ethically approved Research Tissue Bank protocol enables us to prospectively collect samples tailored to your research requirements.
hLAB provides long term storage solutions for biological samples and compounds. Our storage facilities operate under GMP and GDP regulations, exceeding industry standards to maintain the integrity and security of your samples. Fully HTA licensed and approved for GMM storage, our facilities are equipped to handle materials up to Biohazard Category 3. A Home Office licence for controlled drugs further ensures secure, compliant storage for the biotech, pharmaceutical, and healthcare industries.
Driving innovation in cardiometabolic research with deep expertise, advanced diagnostics, and end-to-end clinical support.
Accelerating dermatology innovation through expert-led studies, advanced assessments, and rapid patient recruitment.
Driving innovation in infectious disease clinical trials through expert study design, rapid recruitment, and scientifically rigorous execution.
Expertly designed early-phase trials in renal and hepatic impairment to ensure safe, effective therapies for patients with compromised organ function.
Advancing respiratory health through expertly designed trials, specialist assessments, and targeted patient recruitment.
Factsheet
Increasing awareness of RSV, a common virus that can cause severe respiratory infections, especially in young children and the elderly.
Read MoreScientific Paper
Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies
Read MoreKeep up to date with hVIVO's regulatory news by email alerts.
See the latest media stories featuring hVIVO.
Official media resources for press and publications.
Access videos, interviews, and visual media from hVIVO.
Stay updated on hVIVO’s participation in industry events.
hVIVO is a publicly traded company on the London Stock Exchange AIM Market under the symbol HVO
Watch hVIVO’s July 2024 Capital Markets Day here
The information disclosed in this section and elsewhere within the website is in accordance with Rule 26 of AIM Rules for Companies. The following information is disclosed in accordance with AIM Rule 26. Updated 21 July 2025.
hVIVO plc has operations in the UK, France, the Netherlands, Germany, and Ireland, and the main country of operation is the UK.
Country of Incorporation:
England & Wales
Company registration number:
7514939
Registered address:
40 Bank Street
Floor 24
London
E14 5NR
Total number of shares issued:
Ordinary shares
Go to significant shareholder
Pursuant to the AIM rules, and insofar as it is aware, at 21 July 2025, 27.33% of the Company’s securities were not in public hands. There are no shares held in treasury.
The Company Documents can be found here.
The Company is subject to the UK City Code on Takeovers and Mergers.
There are no restrictions on the transfer of ordinary shares.
Annual and Half Yearly Reports & Accounts can be found here.
The shares of the Company are traded on the AIM market operated by the London Stock Exchange.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
